应用胺碘酮预防食管癌术后房颤的疗效及安全性评价

Efficacy and safty of Amiodarone in preventing atrial fibrillation after transthoracic esophagectomy

摘要:

目的：评价开胸食管癌切除术前预防性应用胺碘酮对术后房颤（Atrial fibrillation，AF）预防的作用和安全性。方法：72例连续手术患者随机分为实验组（n=36）和对照组（n=36），实验组患者于术前给予口服200 mg，3次/d，7 d后，改为200 mg，1次/d，至手术前。观察术后AF发生率、胺碘酮不良反应、其他并发症发生率和住院时间。结果：2组患者人口统计学特征无明显差异；实验组的AF发生率和AF时的心室率低于对照组[16.7% vs. 39.8%；（112±22）次/min vs. （134±29）次/min，P<0.05]。2组在术后并发症发生率和住院时间无统计学差异（P>0.05）。结论：术前预防性应用胺碘酮可以降低开胸食管癌患者术后AF的发生率。

Abstract:

Objective：To determine the efficacy and safety of Amiodarone in preventing atrial fibrillation（AF） after transthoracic esophagectomy. Methods：Seventy-two patients undergoing transthoracic esophagectomy consecutively were randomly divided into ex－perimental group（n=36） and control group（n=36）. Amiodarone-treated patients received Amiodarone in a dose of 200 mg three times per day for 7 d，then 200 mg per day until the day of surgery. The incidence of AF，hospital duration，occurrence of other complications and adverse events in the two groups were compared. Results：There was no significant difference between experimental and control groups in demographic characteristics. The incidence of AF was lower in experimental group than in control group（16.7% vs. 39.8 %，（112±22） times/min vs. （134±29） times/min，P<0.05）. There was no significant difference between the groups in incidences of postoperative complications and hospital duration. Conclusion：Amiodarone prophylaxis can significantly reduce the incidence of AF after transthoracic esophagectomy.